Proactive Investors - Run By Investors For Investors

Evgen Pharma raises £2.3mln to fund its two clinical trials

The proceeds from the share sale will be used to progress two phase II clinical trials
vials be processed
The proceeds from the share sale will be used to progress two phase II clinical trials involving patients with subarachnoid haemorrhage (a type of stroke) and metastatic breast cancer

Evgen Pharma plc (LON:EVG) has applied a meaty discount to its shares in order to get its £2.3mln fundraiser away.

Investors who took part in the placing received new paper at 12p. The stock, which closed at 17p on Thursday after opening at 20.5p, was changing hands for around 27p in October and almost 30p in February.

READ: Evgen Pharma and the power of plants for potential drug breakthrough

The proceeds from the share sale will be used to progress two phase II clinical trials involving patients with subarachnoid haemorrhage (a type of stroke) and metastatic breast cancer.

The company in its half-yearly update said it is making “exciting progress” with the studies and will be reporting data next year.

READ: Evgen Pharma shares jump after positive updates on two Phase II clinical trials for its SFX-01 treatment

“The additional funds will provide valuable working capital as we drive forward our pioneering work in sulforaphane-based therapeutics," said chief executive Steve Franklin.

View full EVG profile View Profile

Evgen Pharma Timeline

Article
October 21 2015

Related Articles

scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
pippette
November 23 2018
The Australian regenerative medicine company is developing a portfolio of innovative cellular therapies targeting significant unmet medical needs with a licence-driven strategy.
1534940807_rsz_shutterstock_130327115.jpg
August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use